This company is no longer active
The company may no longer be operating, as it may be out of business. Find out why through their latest events.
Ekso Bionics Holdings (EKSO) 주식 개요
는 미주, 유럽, 중동, 아프리카, 아시아 태평양 및 전 세계에서 외골격 제품을 설계, 개발, 유통 및 상용화하는 회사입니다. 자세히 보기
EKSO Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ekso Bionics Holdings, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$11.80 |
| 52주 최고가 | US$13.50 |
| 52주 최저가 | US$2.73 |
| 베타 | 0.78 |
| 1개월 변동 | 25.53% |
| 3개월 변동 | 30.10% |
| 1년 변동 | 65.13% |
| 3년 변동 | -49.89% |
| 5년 변동 | -84.70% |
| IPO 이후 변동 | -99.68% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Apr 23
EKSO: Going Concern Warning Will Drive Bearish Outlook On Shares
Analysts have maintained their $9.50 price target for Ekso Bionics Holdings, noting that only modest adjustments were made to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major change to the overall investment case. What's in the News Auditor WithumSmith+Brown, PC issued an unqualified opinion in the 10-K filed on February 23, 2026, while also expressing doubt about Ekso Bionics Holdings' ability to continue as a going concern, highlighting liquidity and sustainability questions for shareholders (Key Developments).내러티브 업데이트 • Apr 09
EKSO: Going Concern Risk And Capital Raises Will Shape Balanced Outlook
Analysts have kept their $9.50 price target for Ekso Bionics Holdings unchanged, pointing to only minor tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions as the reason for holding steady. What's in the News Filed Form 10-K for the year ended December 31, 2025, with auditor WithumSmith+Brown, PC issuing an unqualified opinion that includes doubt about Ekso Bionics Holdings continuing as a going concern (10-K filing).내러티브 업데이트 • Mar 25
EKSO: Reverse Merger And Going Concern Risk Will Drive Bearish Outlook
Analysts have modestly adjusted their price target for Ekso Bionics Holdings, citing small updates to inputs such as the discount rate, an assumed long term revenue growth rate of about 33.71%, and a future P/E assumption of about 43.20x. Taken together, these inputs leave their view of fair value steady at $9.50 per share.Recent updates
내러티브 업데이트 • Apr 23
EKSO: Going Concern Warning Will Drive Bearish Outlook On Shares
Analysts have maintained their $9.50 price target for Ekso Bionics Holdings, noting that only modest adjustments were made to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major change to the overall investment case. What's in the News Auditor WithumSmith+Brown, PC issued an unqualified opinion in the 10-K filed on February 23, 2026, while also expressing doubt about Ekso Bionics Holdings' ability to continue as a going concern, highlighting liquidity and sustainability questions for shareholders (Key Developments).내러티브 업데이트 • Apr 09
EKSO: Going Concern Risk And Capital Raises Will Shape Balanced Outlook
Analysts have kept their $9.50 price target for Ekso Bionics Holdings unchanged, pointing to only minor tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions as the reason for holding steady. What's in the News Filed Form 10-K for the year ended December 31, 2025, with auditor WithumSmith+Brown, PC issuing an unqualified opinion that includes doubt about Ekso Bionics Holdings continuing as a going concern (10-K filing).내러티브 업데이트 • Mar 25
EKSO: Reverse Merger And Going Concern Risk Will Drive Bearish Outlook
Analysts have modestly adjusted their price target for Ekso Bionics Holdings, citing small updates to inputs such as the discount rate, an assumed long term revenue growth rate of about 33.71%, and a future P/E assumption of about 43.20x. Taken together, these inputs leave their view of fair value steady at $9.50 per share.내러티브 업데이트 • Mar 11
EKSO: Reverse Merger Uncertainty Will Drive Bearish Long Term Outlook
Analysts have nudged their price target on Ekso Bionics Holdings higher to $9.50 per share, reflecting updated assumptions around revenue growth, profit margin and a lower forward P/E. Together, these factors support a stronger long term valuation case at the same fair value estimate of $9.50.내러티브 업데이트 • Feb 24
EKSO: Reverse Merger And Revenue Slowdown Will Shape Cautious Outlook
Analysts have maintained their $9.50 price target on Ekso Bionics Holdings, citing only minor adjustments to inputs such as the discount rate, long term revenue growth assumptions, profit margin and future P/E that do not materially alter their valuation view. What’s in the News Applied Digital Cloud Corporation signed a letter of intent to acquire Ekso Bionics Holdings in a reverse merger, with Applied Digital expected to own about 97% of the combined company.내러티브 업데이트 • Feb 10
EKSO: Q3 Sales Recovery And Business Review Will Shape Balanced Outlook
Analysts have lifted their price target on Ekso Bionics Holdings to US$6 from US$4, citing a solid Q3 update and a company-led review of its current business as key supports for the revised valuation outlook. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher US$6 price target as a reflection of increased confidence in the company’s ability to execute on its current business plan following the Q3 update.내러티브 업데이트 • Jan 27
EKSO: Q3 Sales Recovery And Business Review Will Drive Future Upside
Narrative Update Analysts have lifted their price target on Ekso Bionics Holdings to $6 from $4, citing a solid Q3 report, a newly announced review of the current business, and signs that earlier order delays may have been specific to prior periods rather than ongoing. Analyst Commentary Analysts raising their price target to $6 from $4 are reacting to the recent Q3 report and the announced review of the current business, while still flagging a few key execution risks that could affect how the story plays out from here.내러티브 업데이트 • Jan 12
EKSO: Q3 Sales Recovery And Business Review Will Support Future Upside
Analysts have lifted their fair value estimate for Ekso Bionics Holdings from $7.75 to $9.50, citing a higher Street price target of $6.00, a solid Q3 report, and the ongoing review of the current business as key reasons for the reassessment. Analyst Commentary Recent Street research reflects a mix of optimism and caution around Ekso Bionics Holdings, with the latest price target move to US$6 framed around the recent Q3 report and the ongoing review of the current business.내러티브 업데이트 • Dec 26
EKSO: Q3 Sales Recovery And Business Review Will Drive Future Upside
Analysts have modestly raised their price target on Ekso Bionics Holdings to $6 from $4, citing a solid Q3 performance and signs that earlier order delays were idiosyncratic, even as they await further confirmation that the recent sales recovery is sustainable. Analyst Commentary Bullish analysts view the higher price target as a reflection of improving execution and a clearer path to value creation following the strong Q3 report and strategic review announcement.분석 기사 • Dec 23
Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) Shares Bounce 29% But Its Business Still Trails The Industry
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shares have had a really impressive month, gaining 29% after a shaky period...
내러티브 업데이트 • Dec 12
EKSO: Q3 Sales Momentum Is Expected To Drive Shares Higher
Analysts have raised their price target on Ekso Bionics Holdings to $6.00 from $4.00, citing stronger than expected Q3 sales momentum, a modestly lower perceived risk profile, and improved long term growth and profitability assumptions. Analyst Commentary Bearish analysts acknowledge that the higher price target reflects a solid Q3, but emphasize that the implied upside is increasingly reliant on sustained execution against a still-early sales recovery.내러티브 업데이트 • Nov 27
EKSO: Sales Recovery and Increased Confidence Will Drive Future Stock Performance
Analysts have raised their price target for Ekso Bionics from $6.75 to $7.75. This change reflects stronger revenue growth expectations and a solid recent earnings report.분석 기사 • Aug 24
Take Care Before Jumping Onto Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Even Though It's 26% Cheaper
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shares have had a horrible month, losing 26% after a relatively good period...내러티브 업데이트 • Aug 10
Advanced Exoskeleton Devices Will Broaden Rehabilitation Market Access
The drastic reduction in Ekso Bionics Holdings' consensus price target from $34.75 to $6.75 reflects sharply lower growth and earnings expectations as seen in the substantial drop in its forward P/E multiple from 24.94x to 4.86x. What's in the News Launched eksoUniversity, an online platform offering CEU-approved courses for physical therapists and assistants in over 30 states.분석 기사 • Jun 22
Not Many Are Piling Into Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Stock Yet As It Plummets 31%
Unfortunately for some shareholders, the Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) share price has dived 31% in the...분석 기사 • Jun 22
Slammed 31% Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Screens Well Here But There Might Be A Catch
To the annoyance of some shareholders, Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shares are down a considerable 31...
새로운 내러티브 • May 01
PRIA Healthcare And National Seating Will Streamline Medicare Claims
Strategic partnerships aim to broaden distribution, streamline reimbursements, and enhance revenue growth in the personal health market.분석 기사 • Mar 07
It's Down 27% But Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Could Be Riskier Than It Looks
Unfortunately for some shareholders, the Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) share price has dived 27% in the...분석 기사 • Mar 06
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
It's been a sad week for Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ), who've watched their investment drop 17% to...분석 기사 • Jan 12
Even With A 39% Surge, Cautious Investors Are Not Rewarding Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) Performance Completely
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shareholders are no doubt pleased to see that the share price has bounced...분석 기사 • Nov 12
Take Care Before Jumping Onto Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Even Though It's 27% Cheaper
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shareholders that were waiting for something to happen have been dealt a...분석 기사 • Aug 29
Investors Give Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Shares A 26% Hiding
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shares have had a horrible month, losing 26% after a relatively good period...분석 기사 • Jul 13
Many Still Looking Away From Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)
Ekso Bionics Holdings, Inc.'s ( NASDAQ:EKSO ) price-to-sales (or "P/S") ratio of 1.2x might make it look like a buy...분석 기사 • May 02
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00
It's shaping up to be a tough period for Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ), which a week ago released some...분석 기사 • Dec 20
Market Still Lacking Some Conviction On Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)
You may think that with a price-to-sales (or "P/S") ratio of 1.3x Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) is a...분석 기사 • Jun 19
Sentiment Still Eluding Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)
Ekso Bionics Holdings, Inc.'s ( NASDAQ:EKSO ) price-to-sales (or "P/S") ratio of 1.1x might make it look like a strong...주주 수익률
| EKSO | US Medical Equipment | US 시장 | |
|---|---|---|---|
| 7D | 3.8% | 1.7% | -0.7% |
| 1Y | 65.1% | -20.1% | 17.3% |
수익률 대 산업: EKSO은 지난 1년 동안 -20.1%의 수익을 기록한 US Medical Equipment 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: EKSO은 지난 1년 동안 17.3%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| EKSO volatility | |
|---|---|
| EKSO Average Weekly Movement | 12.3% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: EKSO의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.
시간에 따른 변동성: EKSO의 주간 변동성은 지난 1년간 19%에서 12%로 감소했지만 여전히 US 종목의 상위 75%보다 높습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2005 | 53 | Scott Davis | www.eksobionics.com |
는 미주, 유럽, 중동, 아프리카, 아시아 태평양 및 전 세계에서 외골격 제품을 설계, 개발, 유통 및 상용화하고 있습니다. 이 회사는 웨어러블 로봇 외골격인 EksoNR, 전동 외골격인 Ekso Indego Therapy, 전동 하지 보조기인 Ekso Indego Personal, 웨어러블 상체 외골격인 Ekso EVO를 제공합니다. 또한 전동 무릎 발목 발 보조기인 Ekso Nomad와 다방향 섭동 트레드밀이 장착된 재활 시스템인 메디터치 밸런스튜터(MediTouch BalanceTutor)도 개발했습니다.
Ekso Bionics Holdings, Inc. 기초 지표 요약
| EKSO 기초 통계 | |
|---|---|
| 시가총액 | US$42.01m |
| 순이익 (TTM) | -US$15.91m |
| 매출 (TTM) | US$11.57m |
3.6x
주가매출비율(P/S)-2.6x
주가수익비율(P/E)EKSO는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| EKSO 손익계산서 (TTM) | |
|---|---|
| 매출 | US$11.57m |
| 매출원가 | US$5.45m |
| 총이익 | US$6.11m |
| 기타 비용 | US$22.03m |
| 순이익 | -US$15.91m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -4.47 |
| 총이익률 | 52.86% |
| 순이익률 | -137.61% |
| 부채/자본 비율 | 67.0% |
EKSO의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/04 00:48 |
| 종가 | 2026/05/04 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Ekso Bionics Holdings, Inc.는 7명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Gregory Chodaczek | B. Riley Securities, Inc. |
| Tom Grady | Edison Investment Research |
| Dan Scovel | Edison Investment Research |